My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Plerixafor (AMD 3100)
    Plerixafor (AMD 3100)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1488
    CAS #: 110078-46-1 Purity ≥98%

    Description: Plerixafor (formerly known as SDZ-SID-791; JLK-169; SID-791; AMD3100, AMD-3100, JM-3100, JM 3100; trade name Mozobil), the so called 'hematopoeitic stem cell mobilizer', is a novel and potent chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with an IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity and has been approved as an immunostimulant to mobilize hematopoietic stem cells in cancer patients into the bloodstream. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. 

    References: J Immunol. 2009 Sep 1;183(5):3204-11; J Invest Dermatol. 2012 Mar;132(3 Pt 1):711-20.

    Related CAS#: 155148-31-5 (HCl)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)502.78
    CAS No.110078-46-1(free base); 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO:<1 mg/mL
    Water: 3 mg/mL (5.96 mM)
    Ethanol: 100 mg/mL (198.9 mM) 
    Solubility (In vivo)30% Propylene glycol, 5% Tween 80, 65% D5W: 30 mg/mL  
    SynonymsJM-3100; AMD3100; AMD 3100; JM-3100; AMD-3100; SDZ-SID-791; JLK-169; SID-791; JM-2987; Plerixafor HCl; MOZOBIL.

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Plerixafor inhibits CXCL12-mediated chemotaxis with a potency lightly better than its affinity for CXCR4. Plerixafor also antagonizes SDF-1/CXCL12 ligand binding with an IC50 of 651 nM. Plerixafor inhibits SDF-1 mediated GTP-binding, SDF-1 mediated calcium flux and SDF-1 stimulated chemotaxis with IC50 of 27 nM, 572 nM and 51 nM, respectively. Plerixafor does not inhibit calcium flux against cells expressing CXCR3, CCR1, CCR2b, CCR4, CCR5 or CCR7 when stimulated with their cognate ligands, nor does Plerixafor inhibit receptor binding of LTB4. Plerixafor does not, on its own, induce a calcium flux in the CCRF–CEM cells, which express multiple GPCRs including CXCR4, CCR4 and CCR7.

    Kinase Assay: For the competition binding studies against CXCR4, a concentration range of Plerixafor was incubated for 3 hours at 4°C in binding buffer (PBS containing 5 mM MgCl2, 1 mM CaCl2, 0.25% BSA, pH 7.4) with 5 × 105 CCRF-CEM cells and 100 pM 125I-SDF-1α (2200 Ci/mmol) in Milipore DuraporeTM filter plates. Unbound 125I-SDF-1α was removed by washing with cold 50 mM HEPES, 0.5 M NaCl pH 7.4. The competition binding assay against BLT1 was performed on membranes from CHO-S cells expressing recombinant BLT1. The membranes were prepared by mechanical cell lysis followed by high speed centrifugation, re-suspended in 50 mm HEPES, 5 mM MgCl2 buffer and flash frozen. The membrane preparation was incubated with Plerixafor for 1 hour at room temperature in an assay mixture containing 50 mM Tris, pH 7.4, 10 mM MgCl2, 10 mM CaCl2, 4 nM LTB4 mixed with 1 nM 3H-LTB4 (195.0 Ci/mmol) and 8 μg membrane. The unbound 3H-LTB4 is separated by filtration on Millipore Type GF-C filter plates.

    Cell Assay: CXCR4 and SDF-1 were key factors in regulating cancer cell invasion and metastasis, and Plerixafor effectively prevented the binding of SDF-1 to CXCR4, inhibiting cancer metastasis.

    In VivoCohorts of mice were administered with PBS, IGF1, PDGF, SCF or VEGF for five consecutive days and Plerixafor on the 5th day. The number and size of the colonies were highest in mice injected with IGF1 and Plerixafor than those treated with PDGF, SCF or VEGF plus Plerixafor.
    Animal modelC57BL/6 mice with segmental bone defect
    Formulation & Dosage5 mg/kg; i.p. injection

    J Immunol. 2009 Sep 1;183(5):3204-11; Biochem Pharmacol. 2006 Aug 28;72(5):588-96; Bone. 2012 Apr;50(4):1012-8.

    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Plerixafor (AMD3100)


    Plerixafor (AMD3100)

    Wound-healing in diabetic mice. J Invest Dermatol. 2012 Mar;132(3 Pt 1):711-20.

    Plerixafor (AMD3100)

    J Invest Dermatol. 2012 Mar;132(3 Pt 1):711-20.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?